Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Current Medical Research and Opinion|September 11, 2009
Development and psychometric properties of the HPV Impact Profile (HIP) to assess the psychosocial burden of HPVT Christopher Mast, Xingshu Zhu, Carla Demuro-Mercon, et al.
Expert Review of Vaccines|August 23, 2021
Public health impact of pneumococcal conjugate vaccination: a review of measurement challengesEmily K Horn, Matt D Wasserman, Cassandra Hall-Murray, et al.
Expert Review of Vaccines|December 15, 2015
Pneumococcal conjugate vaccine use in adultsRaul E Isturiz, Beate Schmoele-Thoma, Daniel A Scott, et al.
Vaccine|September 17, 2019
Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysisJohn M McLaughlin, Qin Jiang, Bradford D Gessner, et al.
Expert Review of Vaccines|October 8, 2019
The impact of pneumococcal conjugate vaccines on serotype 19A nasopharyngeal carriageMyint Tin Tin Htar, Heather L Sings, Maria Syrochkina, et al.
The Journal of Infection|August 3, 2020
Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009‒2017Jose A Suaya, Rodrigo E Mendes, Heather L Sings, et al.
The Journal of Infectious Diseases|February 10, 2009
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccineSuzanne M Garland, Marc Steben, Heather L Sings, et al.
Infectious Diseases and Therapy|April 10, 2020
Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective AnalysisMichele R Wilson, Matthew D Wasserman, Marie-Claude Breton, et al.
Vaccine|March 22, 2012
Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and femalesRongcheng Li, Yanping Li, David Radley, et al.
American Journal of Obstetrics and Gynecology|March 4, 2008
Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American womenEliav Barr, Christine K Gause, Oliver M Bautista, et al.
Pageof 6